• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    BitNile Holdings Plans to Change Name to Ault Alliance

    12/20/22 6:30:00 AM ET
    $ADRT
    $ALZN
    $MICS
    $NILE
    Blank Checks
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADRT alert in real time by email

    BitNile Holdings, Inc. (NYSE:NILE), a diversified holding company ("BitNile" or the "Company"), today announced its plan to merge its wholly owned subsidiary, Ault Alliance, Inc. ("AAI") with and into BitNile. In connection with this upstream merger, the current AAI will disappear and the business of BitNile will continue as it is currently being conducted. Further, on January 3, 2023, the effective date of the merger, the Company will change its name to Ault Alliance, Inc. and its ticker will be changed to "AULT."

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221220005271/en/

    The Company's Founder and Executive Chairman, Milton "Todd" Ault, III said, "The name change to Ault Alliance reflects the changes we began to build in 2017 and grow to become the diversified holding company we are today. We have built a diversified portfolio of companies with assets totaling more than $600 million. In the months ahead, we plan to operate in three main segments.

    • Energy and Infrastructure:
      • Ault Energy, LLC – oil exploration;
      • Circle 8 Newco LLC – crane operations;
      • Avalanche International Corp. – multiplexed laser surface enhancement of textiles;
      • Investment in Eco Pack Technologies; and
      • Investment in Unique Electric Solutions.
    • Technology and Finance:
      • Ault Lending, LLC – California Finance Lending License #60DBO-77905;
      • The Singing Machine Company – (NASDAQ:MICS) consumer electronics;
      • BitNile, Inc. – Bitcoin mining operations;
      • Ault Disruptive Technologies Corp. – (NYSE:ADRT) special purpose acquisition company;
      • Investment in Alzamend Neuro, Inc. – (NASDAQ:ALZN) biopharma;
      • Investment in Adtech Pharma, Inc. – biotechnology; and
      • Investment in Earnity Inc. – decentralized finance platform.
    • Hotels, Real Estate and Data Center:
      • Ault Global Real Estate Equities, Inc.;
        • Four Midwest Marriott and Hilton hotels;
        • St. Petersburg, Florida land development project;
      • Alliance Cloud Services, LLC – the Michigan data center; and
      • Limited partnership investment in Hotel Fouquet's New York.

    The attributed assets do not reflect all the assets owned by the Company, such as equity investments in other private and public companies. The Company plans to file a list of all assets each quarter.

    As previously announced, the Company plans to spin off Imperalis Holding Corp. (to be renamed TurnOnGreen, Inc.) and Giga-tronics Incorporated and excluding revenue from the announced spin-offs expects revenue of more than $200 million for 2023. We are pleased with the positioning and strategic direction of the Company. We are committed in our Bitcoin mining endeavors as a key component of our technology and finance segment. As Ault Alliance, we plan to make the Company's structure and focus clear, precise and understandable. We are dedicated to enhancing stockholder value and continuing to improve our financial results, we plan to maximize the returns of our existing investments, which are positioned for growth, and we do not expect to make significant acquisitions within the next year."

    For more information on BitNile Holdings and its subsidiaries, the Company recommends that stockholders, investors and any other interested parties read the Company's public filings and press releases available under the Investor Relations section at www.BitNile.com or available at www.sec.gov.

    About BitNile Holdings, Inc.

    BitNile Holdings, Inc. is a diversified holding company pursuing growth by acquiring undervalued businesses and disruptive technologies with a global impact. Through its wholly and majority-owned subsidiaries and strategic investments, BitNile owns and operates a data center at which it mines Bitcoin and provides mission-critical products that support a diverse range of industries, including oil exploration, crane services, defense/aerospace, industrial, automotive, medical/biopharma, consumer electronics, hotel operations and textiles. In addition, BitNile extends credit to select entrepreneurial businesses through a licensed lending subsidiary. BitNile's headquarters are located at 11411 Southern Highlands Parkway, Suite 240, Las Vegas, NV 89141; www.BitNile.com.

    Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "believes," "plans," "anticipates," "projects," "estimates," "expects," "intends," "strategy," "future," "opportunity," "may," "will," "should," "could," "potential," or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties. Forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update any of them publicly in light of new information or future events. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. More information, including potential risk factors, that could affect the Company's business and financial results are included in the Company's filings with the U.S. Securities and Exchange Commission, including, but not limited to, the Company's Forms 10-K, 10-Q and 8-K. All filings are available at www.sec.gov and on the Company's website at www.BitNile.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20221220005271/en/

    Get the next $ADRT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ADRT
    $ALZN
    $MICS
    $NILE

    CompanyDatePrice TargetRatingAnalyst
    Alzamend Neuro Inc.
    $ALZN
    10/1/2021$8.00Buy
    Ascendiant Capital Markets
    More analyst ratings

    $ADRT
    $ALZN
    $MICS
    $NILE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule

      ATLANTA, June 16, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced that it has completed the final closing of its $5 million private placement. As previously reported, on February 28, 2025, Alzamend entered into a Securities Purchase & Exchange Agreement (the "Agreement") with a sophisticated investor (the "Investor"), pursuant to which Alzamend agreed to sell to the Investor up to 500 shares of Series C Conver

      6/16/25 8:00:00 AM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital

      Topline data expected by year endHead-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 29, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced the dosing of the first patient of its first Phase II clinical study of AL001, in healthy human subjects. This study follows th

      5/29/25 8:00:00 AM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital

      Topline data expected by year endHead-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 19, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced the enrollment of the first patient of its first Phase II clinical study of AL001, in healthy human subjects. This study follow

      5/19/25 8:00:00 AM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADRT
    $ALZN
    $MICS
    $NILE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ault Milton C Iii sold $6,196 worth of shares (1,224 units at $5.06), decreasing direct ownership by 0.59% to 1,843 units (SEC Form 4)

      4 - Alzamend Neuro, Inc. (0001677077) (Issuer)

      5/14/25 5:00:07 PM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Horne William B. bought $3,285 worth of shares (3,334 units at $0.99), increasing direct ownership by 13% to 30,000 units (SEC Form 4)

      4 - Alzamend Neuro, Inc. (0001677077) (Issuer)

      3/27/25 7:30:10 AM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ault Milton C Iii bought $2,969 worth of shares (2,905 units at $1.02) (SEC Form 4)

      4 - Alzamend Neuro, Inc. (0001677077) (Issuer)

      3/25/25 4:30:07 PM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADRT
    $ALZN
    $MICS
    $NILE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Horne William B. bought $3,285 worth of shares (3,334 units at $0.99), increasing direct ownership by 13% to 30,000 units (SEC Form 4)

      4 - Alzamend Neuro, Inc. (0001677077) (Issuer)

      3/27/25 7:30:10 AM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ault Milton C Iii bought $2,969 worth of shares (2,905 units at $1.02) (SEC Form 4)

      4 - Alzamend Neuro, Inc. (0001677077) (Issuer)

      3/25/25 4:30:07 PM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Katzoff David J bought $5,048 worth of shares (5,000 units at $1.01), increasing direct ownership by 926% to 5,540 units (SEC Form 4)

      4 - Alzamend Neuro, Inc. (0001677077) (Issuer)

      3/24/25 7:30:07 AM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADRT
    $ALZN
    $MICS
    $NILE
    SEC Filings

    See more
    • Amendment: SEC Form 144/A filed by Alzamend Neuro Inc.

      144/A - Alzamend Neuro, Inc. (0001677077) (Subject)

      7/11/25 7:15:38 PM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alzamend Neuro Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - Alzamend Neuro, Inc. (0001677077) (Filer)

      7/9/25 4:30:40 PM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Alzamend Neuro Inc.

      144 - Alzamend Neuro, Inc. (0001677077) (Subject)

      5/9/25 7:49:16 PM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADRT
    $ALZN
    $MICS
    $NILE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ascendiant Capital Markets initiated coverage on Alzamend Neuro with a new price target

      Ascendiant Capital Markets initiated coverage of Alzamend Neuro with a rating of Buy and set a new price target of $8.00

      10/1/21 7:11:54 AM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADRT
    $ALZN
    $MICS
    $NILE
    Leadership Updates

    Live Leadership Updates

    See more
    • BitNile Holdings Announces Results of Annual Meeting of Stockholders

      BitNile Holdings, Inc. (NYSE:NILE), a diversified holding company ("BitNile" or the "Company"), announced the results of the Company's 2022 Annual Meeting of Stockholders (the "Meeting"), which was held today, November 23, 2022, at 9:00 a.m. PT, and at which time the nominees for election as directors set forth in Proposal 1 were each re-elected and Proposals 2, 3, 6 and 7 were each approved by the stockholders. Proposals 4 and 5 were not approved by the stockholders. At the Meeting, the stockholders voted upon and approved the following proposals as described in the Proxy Statement: Election of the seven director nominees named in the Proxy Statement to hold office until the next annual

      11/23/22 12:11:00 PM ET
      $NILE
      Military/Government/Technical
      Industrials
    • BitNile, Inc. to Launch Innovative Bitcoin Marketplace Platform Intended to Reimagine Cryptocurrency Transactions

      Company Appoints Veteran Developer Douglas Gintz as President and Chief Product Officer to Lead the Effort BitNile Holdings, Inc. (NYSE:NILE), a diversified holding company ("BitNile" or the "Company"), announced today that its subsidiary, BitNile, Inc. ("BNI"), has begun development of a Bitcoin-based marketplace platform ("Marketplace"), which expects to leverage blockchain and other emerging technologies. BNI believes that the Marketplace will reduce the complexity of transacting in Bitcoin and result in lower transaction fees than traditional e-commerce. The Marketplace, planned for release in the first half of 2023, will be a multi-vendor e-commerce platform supporting a wide array of

      10/13/22 6:30:00 AM ET
      $NILE
      Military/Government/Technical
      Industrials
    • Alzamend Neuro Appoints Dr. Terri Hunter to Its Scientific Advisory Board

      Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced the appointment of Dr. Terri Hunter, Ph.D., a Technology Transfer Specialist, to its Scientific Advisory Board. During her tenure at the University of South Florida ("USF"), Dr. Hunter was responsible for managing the patent portfolio associated with Alzamend's two product candidates, AL001 and AL002. AL001 is a novel lithium-delivery system; it is a lithium-salicylate-L-proline engineered ionic co-crystal under development as an oral treatment for patients with demen

      4/4/22 8:00:00 AM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADRT
    $ALZN
    $MICS
    $NILE
    Financials

    Live finance-specific insights

    See more
    • Singing Machine Announces Corporate Rebrand to Algorhythm Holdings, Inc.

      Strategic Rebranding to Focus on Expanded Business Model and Growth Strategy. New Ticker RIME. Fort Lauderdale, FL, Sept. 05, 2024 (GLOBE NEWSWIRE) -- The Singing Machine Company, Inc. ("Singing Machine") (NASDAQ: MICS) – the worldwide leader in consumer karaoke products, recently announced it has successfully completed the acquisition of SemiCab, Inc. ("SemiCab"), a leading artificial intelligence technology company in the global logistics space. As part of this transaction, the Company announced an expanded business model, centered on making investments in AI driven technology companies focused on solving challenges for some of the largest global industry verticals. Today, the Comp

      9/5/24 7:00:00 AM ET
      $MICS
      Diversified Electronic Products
      Consumer Staples
    • Singing Machine to Announce its Financial Results for the Second Quarter of 2024

      Fort Lauderdale, FL, Aug. 14, 2024 (GLOBE NEWSWIRE) -- The Singing Machine Company, Inc. ("Singing Machine" or the "Company") (NASDAQ: MICS) -- the worldwide leader in consumer karaoke products -- today announced that its earnings for its second quarter of 2024 will be released Monday, August 19, 2024. The same day Management will host a conference call at 4:00 PM Eastern time to discuss the financial results and provide a business update. Management will also provide an update on the acquisition integration of SemiCab, an emerging AI-powered technology provider serving the global logistics space. Conference Call Details: Date: Monday August 19, 2024Time: 4:00 PM EDT Dial-in number: 800-

      8/14/24 7:00:00 AM ET
      $MICS
      Diversified Electronic Products
      Consumer Staples
    • Singing Machine's Subsidiary, SemiCab, Announces Over $9 Million Contracted Revenue Backlog

      SemiCab India Expected to Add Over $9 Million in Revenue in 2024 Fort Lauderdale, FL, July 16, 2024 (GLOBE NEWSWIRE) -- The Singing Machine Company, Inc. ("Singing Machine") (NASDAQ: MICS) – the worldwide leader in consumer karaoke products, recently announced it has successfully completed the acquisition of SemiCab, Inc. ("SemiCab"), a leading artificial intelligence technology company in the global logistics space. Today, the Company provided an update on the integration process for the newly created operations under SemiCab Holdings, LLC. The Company currently has key executives in India, completing the final prerequisites for the acquisition of SMCB Solutions Private Limited ("SMCB"

      7/16/24 7:00:00 AM ET
      $MICS
      Diversified Electronic Products
      Consumer Staples

    $ADRT
    $ALZN
    $MICS
    $NILE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Ault Disruptive Technologies Corporation (Amendment)

      SC 13G/A - Ault Disruptive Technologies Corp (0001864032) (Subject)

      2/12/24 4:44:33 PM ET
      $ADRT
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by Ault Disruptive Technologies Corporation (Amendment)

      SC 13G/A - Ault Disruptive Technologies Corp (0001864032) (Subject)

      2/7/24 1:33:12 PM ET
      $ADRT
      Blank Checks
      Finance
    • SEC Form SC 13D/A filed by Alzamend Neuro Inc. (Amendment)

      SC 13D/A - Alzamend Neuro, Inc. (0001677077) (Subject)

      2/2/24 4:38:42 PM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care